Table 5.
Curcumin | ||||
---|---|---|---|---|
Experimental Models |
Concentration Range | Biological Response | Pathway/Genes/Proteins Involved | Refs. |
Cells and Cell Lines | ||||
HCT-116 | 10–25 µM | ↑ Apoptosis | ↓ AP-1, ↓ NF-κB, ↓ MMP-9 |
[95] |
20 µM with 5-FU (5 µM) |
↑ Cell cycle arrest (S) ↑ Apoptosis ↓ Cell proliferation |
↓ caspase-3, ↓ caspase-8, ↓ caspase-9, Bax, ↓ PARP, ↑ Bcl-2 | [96] | |
↓ cyclin D1 | ||||
25 µM with Piperine (7 µM) | ↓ Cell proliferation ↑ Cell cycle arrest (G2/M ↑ Apoptosis |
↓ cyclin D1, ↑ caspase-3 | [97] | |
HT29 | 41 µM | ↓ Oxydative stress ↓ Cell growth, ↓ Invasion, ↓ Metastasis |
↓ NF-E2, ↓ Nrf2 ↓ Bcl-2, ↓ Cyclin D1, ↓ IL6, ↓ Cox2 |
[17] |
HCT-8/5-Fu | 10 µM with 5-FU (10 mM) |
↑ Apoptosis, | ↑ Nrf2, ↑ Bcl-2, ↓ Bax | [98] |
Animal models | ||||
C57BL/6 | 300 mg/kg with DSS (5 mg/kg) I.P. | ↓ Disease activity index, ↓ neoplasic lesions |
↓ β-catenin, Cox2, iNOS | [99] |
↑ Apoptotosis | ↓ cyclinD1, ↓ cyclinD3, ↑ caspase-3, ↑ caspase-7, ↑ caspase-9, ↑ PARP |
[92] | ||
Oxaliplatin-resistant HCT116-xenograft |
(1 g/kg) per os | ↑ Radiosensitivity | ↓ NF-κB, ↓ Ki-67, ↓ Notch-1 |
[100] |
Orthopically implanted CRC tumors (HC116) | (1 g/kg) per os | ↓ Cell growth, ↓ Metastasis |
↓ NF-κB | [91] |